Pharmacokinetics and biodistribution of genetically engineered antibodies.

[1]  S. Batra,et al.  Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. , 2000, Cancer research.

[2]  I. Pastan,et al.  Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII‐specific scFv , 2000, International journal of cancer.

[3]  Y. Lin,et al.  A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. , 2000, Cancer research.

[4]  Y. Shyr,et al.  Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. , 2000, Cancer research.

[5]  P. Hudson.  Recombinant antibodies: a novel approach to cancer diagnosis and therapy , 2000, Expert opinion on investigational drugs.

[6]  G W Beresford,et al.  Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization. , 2000, Journal of biochemistry.

[7]  L. Khawli,et al.  Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  A. Kortt,et al.  High avidity scFv multimers; diabodies and triabodies. , 1999, Journal of immunological methods.

[9]  E. Padlan,et al.  Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  D. Goldenberg,et al.  The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  G W Beresford,et al.  Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  S. Batra,et al.  Effects of genetic engineering on the pharmacokinetics of antibodies. , 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[13]  S. Batra,et al.  Single‐Chain Antibodies in Pancreatic Cancer , 1999, Annals of the New York Academy of Sciences.

[14]  I. Pastan,et al.  Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc. , 1999, Bioconjugate chemistry.

[15]  E. Ward,et al.  FcRn: the MHC class I-related receptor that is more than an IgG transporter. , 1997, Immunology today.

[16]  P. Hand,et al.  A CDR-grafted (humanized) domain-deleted antitumor antibody. , 1997, Cancer biotherapy & radiopharmaceuticals.

[17]  L E Williams,et al.  Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. , 1996, Cancer research.

[18]  E. Padlan,et al.  Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. , 1995, Hybridoma.

[19]  S. Gillies,et al.  Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J N Weinstein,et al.  A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  S. Batra,et al.  Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct , 2000, Cancer Immunology, Immunotherapy.

[22]  S. Batra,et al.  Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis. , 1999, Nuclear medicine and biology.